Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
NCT06595160 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 87
Last updated 2025-08-01
Summary
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma
- Stage I Pancreatic Cancer AJCC v8
Interventions
- OTHER
-
Non-Interventional Study
Non-interventional study
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Emory University
lead OTHER
Principal Investigators
-
Mihir M Shah · Emory University Hospital/Winship Cancer Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-05
- Primary Completion
- 2026-04-30
- Completion
- 2027-08-07
Countries
- United States
Study Locations
More Related Trials
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
NCT02336087 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer
NCT05848154 ·Status: NOT_YET_RECRUITING
-
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
NCT02626520 ·Status: TERMINATED ·Phase: PHASE2
-
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
NCT04975217 ·Status: SUSPENDED ·Phase: EARLY_PHASE1
-
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
NCT05841420 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
NCT03392571 ·Status: WITHDRAWN ·Phase: PHASE2
-
Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer
NCT05596370 ·Status: UNKNOWN
-
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
NCT00003810 ·Status: COMPLETED ·Phase: PHASE2
-
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
NCT00660699 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma
NCT01333124 ·Status: TERMINATED ·Phase: PHASE2
-
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064 ·Status: UNKNOWN ·Phase: PHASE3
-
Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?
NCT06921252 ·Status: COMPLETED
-
Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients
NCT05580887 ·Status: UNKNOWN
-
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
NCT05634564 ·Status: UNKNOWN ·Phase: PHASE2
-
The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
NCT06050395 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
NCT06310902 ·Status: RECRUITING
-
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
NCT00251355 ·Status: COMPLETED ·Phase: PHASE1
-
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
NCT02671890 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
NCT01456585 ·Status: COMPLETED ·Phase: PHASE1
-
Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
NCT02591082 ·Status: COMPLETED
-
Multimodal Therapy Impact on Pancreatic Cancer Survival
NCT06938906 ·Status: ACTIVE_NOT_RECRUITING
-
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
NCT02241551 ·Status: TERMINATED ·Phase: PHASE2
-
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
NCT02318095 ·Status: COMPLETED ·Phase: NA
-
The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome
NCT01989000 ·Status: COMPLETED ·Phase: NA